Seminars in Nuclear Medicine
Volume 37, Issue 1 , Pages 34-47 , January 2007

Single-Photon Emission Computed Tomography/Computed Tomography in Brain Tumors

References 

  1. Del Sole A, Falini A, Ravasi L, et al. Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med. 2001;28:1851–1572
  2. Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull. 1996;52:682–703
  3. Karatsu J, Ushio Y. Epidemiological study of primary intracranial tumours in eldery people. J Neurol Neurosurg Psychiatry. 1997;63:116–118
  4. Smirniotopoulos JG. The new WHO classification of brain tumors. Neuroimag Clin N Am. 1999;9:595–613
  5. De Angelis LM. Brain tumors. N Engl J Med. 2001;344:114–123
  6. Del Sole A, Moncayo R, Tafuni G, et al. Position of nuclear medicine techniques in the diagnostic work-up of brain tumors. Q J Nucl Med Mol Imaging. 2004;48:76–81
  7. Weber DA, Ivanovic M. Correlative image registration. Semin Nucl Med. 1994;24:311–323
  8. Pietrzyk U, Herholz K, Weiss WD. Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr. 1990;14:51–59
  9. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine–applications of dual-modality systems in oncology. Cancer Biother Radiopharm. 2004;19:1–10
  10. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33:205–218
  11. Hutton BF, Braun M, Thurfjell L, et al. Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging. 2002;29:559–577
  12. Treves ST, Mitchell KD, Habboush IH. Three-dimensional image alignment, registration and fusion. J Nucl Med. 1998;42:83–92
  13. van den Elsen PA, Pol EJD, Viergever MA. Medical imaging matching—a review with classification. IEEE Eng Med Biol. 1993;12:26–39
  14. Maintz JB, Viergever MA. A survey of medical imaging registration. Med Image Anal. 1998;2:1–36
  15. Hill DLG, Hawkes DJ, Crossman JE, et al. Registration of MR and CT images for skull base surgery using point-like anatomical features. Br J Radiol. 1991;64:1030–1035
  16. Thirion J. New feature points based on geometric invariants for 3D image registration. Int J Comp Vision. 1996;18:121–137
  17. Pelizzari CA, Chen GT, Spelbring DR, et al. Accurate registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr. 1989;13:20–26
  18. Townsend DW, Cherry SR. Combining anatomy with function: the path to true image fusion. Eur Radiol. 2001;11:1968–19742001
  19. Townsend D, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol. 2002;75(suppl):S24–S30
  20. Lang TF, Hasegawa BH, Liew SC, et al. Description of a prototype emission-transmission computed tomography imaging system. J Nucl Med. 1992;33:1881–1887
  21. Bocher M, Balan A, Krausz Y, et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med. 2000;27:619–627
  22. Schillaci O, Danieli R, Manni C, et al. Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera. Eur J Nucl Med Mol Imaging. 2004;31:1011–1015
  23. Schillaci O, Danieli R, Manni C, et al. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation?. Nucl Med Commun. 2004;25:705–710
  24. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging?. (editorial) Eur J Nucl Med Mol Imaging. 2005;32:521–524
  25. Abdel-Dayem HM, Scott AA, Macapinlac H, et al. Thallium-201 chloride: a tumor imaging agent. In:  Murray IPC,  Ell PJ editor. Nuclear Medicine in Clinical Diagnosis and Treatment (ed 2, vol 2). Edinburgh: Churchill Livingstone; 1998;p. 831–841
  26. Waxman AD. Thallium-201 in nuclear oncology. In:  Freeman LM editors. Nuclear Medicine Annual 1991. New York: Raven Press; 1991;p. 193–209
  27. Ando A, Ando I, Katayama M, et al. Biodistribution of Tl-201 in tumor bearing animals and inflammatory lesion induced animals. Eur J Nucl Med. 1987;12:567–572
  28. Kaplan WD, Takvorian T, Morris JH, et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med. 1987;28:47–52
  29. Sun D, Liu Q, Liu W, et al. Clinical application of Tl-201 SPECT imaging of brain tumors. J Nucl Med. 2000;41:5–10
  30. Kim KT, Black KL, Marciano D, et al. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med. 1999;31:965–969
  31. Ancri D, Basset JY. Diagnosis of cerebral metastases by thallium 201. Br J Radiol. 1980;53:443–453
  32. Datta NR, Pasricha R, Gambhir S, et al. Postoperative residual tumour imaged by contrast-enhanced computed tomography and Tl-201 single photon emission tomography: can they predict progression-free survival in high-grade gliomas?. Clin Oncol (R Coll Radiol). 2004;16:494–500
  33. Lorberboym M, Baram J, Feibel M, et al. A prospective evaluation of thallium-201 single photon emission computerized tomography for brain tumor burden. Int J Radiat Oncol Biol Phys. 1995;32:249–254
  34. Lorberboym M, Mandell LR, Mosesson RE, et al. The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med. 1997;38:223–226
  35. Datta NR, Pasricha R, Gambhir S, et al. Comparative evaluation of Tl-201 SPECT and CT in the follow-up of irradiated brain tumors. Int J Clin Oncol. 2004;9:51–58
  36. Vallejos V, Balana C, Fraile M, et al. Use of Tl-201 SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol. 2002;59:81–90
  37. Scott AM, Macapinlac H, Zhang JJ, et al. Clinical applications of fusion imaging in oncology. Nucl Med Biol. 1994;21:775–784
  38. Hemm S, Rigau V, Chevalier J, et al. Stereotactic coregistration of Tl-201 SPECT and MRI applied to brain tumor biopsies. J Nucl Med. 2005;46:1151–1157
  39. Delman T, Shah NP, Oates ME. Thallium/gallium scintigraphy revisited: added value of SPECT-CT/MR image fusion for characterizing brain lesions. (abstr) Clin Nucl Med. 2006;31:118
  40. Shiraishi S, Tomiguchi S, Utsunomiya D, et al. Quantitative analysis and effect of attenuation correction on lymph node staging of non–small cell lung cancer on SPECT and CT. AJR Am J Roentgenol. 2006;186:1450–1457
  41. Maffioli L, Steens J, Pauwels E, et al. Applications of Tc99m-sestaMIBI in oncology. Tumori. 1996;82:12–21
  42. Schomacker K, Schicha H. Use of myocardial imaging agents for tumour diagnosis - a success story?. Eur J Nucl Med. 2000;27:1845–1863
  43. Schillaci O, Spanu A, Madeddu G. [(99m)Tc]sestamibi and [(99m)Tc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging. 2005;49:133–144
  44. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcelluar distribution and analysis of Tc-99m MIBI in isolated perfused rat hearts. J Nucl Med. 1992;33:1516–1521
  45. Delmon-Mongeon LI, Piwinica-Worms D, Van der Abbeele AD, et al. Uptake of the cation hexakis (2-methoxyisobutilisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990;50:2198–2202
  46. Maublant J, Zhang Z, Rapp M, et al. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med. 1993;34:1949–1952
  47. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med. 1994;21:984–987
  48. Pwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977–984
  49. Hendrikse NH, Franssen EJ, van der Graaf WT, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med. 1999;26:283–293
  50. Perek N, Denoyer D. The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection. Curr Drug Metab. 2002;3:97–113
  51. O’Tuama LA, Treves ST, Larar JN, et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med. 1993;34:1045–1051
  52. Baillet G, Albuquerque L, Chen Q, et al. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med. 1994;21:1061–1066
  53. Bagni B, Pinna L, Tamarozzi R, et al. SPET imaging of intracranial tumours with 99Tcm-sestamibi. Nucl Med Commun. 1995;16:258–264
  54. Maffioli L, Gasparini M, Chiti A, et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med. 1996;23:308–311
  55. Soler C, Beauchesne P, Maatougui K, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med. 1998;25:1649–1657
  56. Jeune FP, Dubois F, Blond S, et al. Sestamibi technetium-99m brain single-photon emission computer tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol. 2005;29:1–7
  57. Beauchesne P, Pedeux R, Boniol M, et al. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med. 2004;45:409–413
  58. Prigent-Le Jeune F, Dubois F, Perez S, et al. Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation f response to chemotherapy: first results. Eur J Nucl Med Mol Imaging. 2004;31:714–719
  59. Kojima T, Mizumura S, Kumita SI, et al. Is technetium-99m-MIBI taken up by the normal pituitary gland? (A comparison of normal pituitary glands and pituitary adenomas). Ann Nucl Med. 2001;15:321–327
  60. Mongioj V, Brusa A, Loi G, et al. Accuracy evaluation of fusion of CT, MR, and spect images using commercially available software packages (SRS PLATO and IFS). Int J Radiat Oncol Biol Phys. 1999;43:227–234
  61. Krengli M, Loi G, Manfredda I, et al. Functional and morphological image fusion for the delineation of target volume in the 3D-treatment plan of high-grade glioma. (abstr) Radiother Oncol. 2004;73:S284
  62. Rajasekar D, Datta NR, Gupta RK, et al. Multimodality image fusion in dose escalation studies of brain tumors. J Appl Clin Med Phys. 2003;4:8–16
  63. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bisbis(2-ethoxyethyl)phpsphinoethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30–38
  64. Arbab AS, Koizumi K, Toyama K, et al. Uptake of technetium-99m-tetrofosmin, technetium-99m-mibi and thallium-201 in tumor cell lines. J Nucl Med. 1996;37:1551–1556
  65. Soricelli A, Cuocolo A, Varrone A, et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with thallium-201 imaging. J Nucl Med. 1998;5:802–806
  66. Choi JY, Kim SE, Shin HJ, et al. Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose. J Neurooncol. 2000;46:63–70
  67. Barai S, Bandopadhayaya GP, Julka PK, et al. Evaluation of single photon emission computerised tomography (SPECT) using Tc99m-tetrofosmin as a diagnostic modality for recurrent posterior fossa tumours. J Postgrad Med. 2003;49:316–321
  68. Filippi L, Santoni R, Manni C, et al. Imaging primary brain tumors by single-photon emission computerized tomography with technetium-99m sestamibi and tetrofosmin. Curr Med Imaging Rev. 2005;1:61–66
  69. Filippi F, Schillaci O, Santoni R, et al. Usefulness of SPECT/CT with a hybrid Camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin. Cancer Biother Radiopharm. 2006;26:41–48
  70. Schillaci O, Danieli R, Tavolaro R, et al. Tc-99m tetrofosmin accumulation in lung cancer and its metastases. Clin Nucl Med. 1997;22:46–47
  71. Filippi L, Santoni R, Manni C, et al. Usefulness of SPECT/CT with a hybrid camera for brain metastases imaging by Tc-99m tetrofosmin. Eur J Nucl Med Mol Imaging. 2006;33:(abstr) (in press)
  72. Bernard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med. 2003;33:148–162
  73. Langen KJ, Ziemons K, Kiwit JCW, et al. 3-(I-123)Iodo-alpha-methyltyrosine and (methyl-C-11)-L-methionine and positron emission tomography. Am J Neuroradiol. 1985;6:505–514
  74. Langen KJ, Roosen N, Coenen HH, et al. Brain and brain tumor uptake of L-3-(I-123)Iodo-alpha-methyltyrosine: competition with natural L-amino acids. J Nucl Med. 1991;32:1225–1228
  75. Biersack HJ, Coenen HH, Stockin G, et al. Imaging of brain tumors with L-3-(I-123)Iodo-alpha-methyltyrosine and SPECT. J Nucl Med. 1989;30:110–112
  76. Matheja P, Rickert C, Weckesser M, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med. 2000;27:550–558
  77. Grosu AL, Weber W, Feldmann HJ, et al. First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys. 2000;47:517–526
  78. Grosu AL, Fieldmann HJ, Dick S, et al. Implications of IMT-SPECT for post-operative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002;54:842–854
  79. Grosu AL, Weber W, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractioned radiotherapy. Int J Radiat Oncol Biol Phys. 2005;65:511–519
  80. Grosu AL, Lachner R, Wiedenmann N, et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys. 2003;56:1450–1463
  81. Plotkin M, Wurm R, Eisenacher J, et al. Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer. Eur Radiol. 2006;16:503–511
  82. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450–482
  83. De Jong M, Bernard HF, de Bruin E, et al. Internalization of radiolabeled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–288
  84. Reubi JC, Lang W, Maurer R, et al. Distribution and characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res. 1987;47:5758–5764
  85. Bakker WH, Krenning EP, Reubi JC, et al. In vivo application of [111In-DTPA-D-Phe1]octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 1991;49:1593–1601
  86. Kwekkeboom D, Krenning EP, de Yong M. peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713
  87. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with In-111-DTPA-D-Phel and (I-125-Tyr3)-octretide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  88. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol. 2003;59:565–573
  89. Schmidt M, Scheidhauer K, Luyken C, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med. 1998;25:675–686
  90. Muller HL, Fruhwald MC, Scheubeck M, et al. A possible role of somatostain receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurol Oncol. 1998;38:27–40
  91. Fruhwald MC, O’Dorisio MS, Pietsch T, et al. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Ped Res. 1999;45:697–708
  92. Laquierre A, Leroux P, Gonzales B, et al. Somatostatin receptors scintigraphy in human cerebellum during development. Brain Res. 1992;573:251–257
  93. Reubi JC, Lang W, Mauer R, et al. Distribution ad biochemical characterization of somatostatin receptors in tumors of the central nervous system. Cancer. 1987;47:5758–5764
  94. Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620–627
  95. Heiderman RL, Packer RJ, Albright LA, et al. Tumors of the central nervous system. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997;p. 633–697
  96. Tobias JS, Hayward RD. Brain and spinal cord tumors in children. In:  Thomas DGT editors. Neurooncology. Baltimore: John Hopkins University Press; 1990;p. 164–192
  97. Torres CF, Rebsamen S, Silber JH, Sutton LN, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med. 1994;330:892–895
  98. Lindsay KL. Surveillance scanning of children with medulloblastoma. N Engl J Med. 1994;331:483
  99. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989;68:844–850
  100. Faglia G, Bazzoni N, Spada A, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of radioiodinated analog of somatostatin ([I-123]SDZ204-090). J Clin Endocrinol Metab. 1991;73:850–856
  101. Ur E, Mather SJ, Bomanji J, et al. Pituitary imaging using a labelled somatostatina analogue in acromegaly. Clin Endocrinol. 1992;36:147–150
  102. Haimes AB, Zimmerman RD, Morgello S. MR imaging of brain abscesses. A J Neuroradiol. 1989;10:279–291
  103. Zimmerman RD, Weingarten K. Neuroimaging of cerebral abscesses. Neuroimaging Clin North Am. 1991;1:1–6
  104. Davidson HD, Steiner RE. Magnetic resonance imaging in infections of the central nervous system. Am J Neuroradiol. 1995;6:499–504
  105. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1:326–333
  106. Bleeker-Rovers CP, Boerman OC, Rennen HJ, et al. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des. 2004;10:2935–2950
  107. Palestro CJ, Swyer AJ, Kim CK, et al. Role of In-111 labeled leukocyte scintigraphy in the diagnosis of intracerebral lesions. Clin Nucl Med. 1991;16:305–308
  108. Grimstad IA, Hirschberg H, Rootwelt K. 99mTc-hexamethyl-propyleneamine oxine leukocyte scintigraphy and C-reactive protein levels in the differential diagnosis of brain absecesses. J Neurosurg. 1992;77:732–736
  109. Kim DG, Lee J, Lee DS, et al. 99m-Tc-HMPAO labeled leukocyte SPECT in intracranial lesions. Surg Neurol. 1995;44:338–345
  110. Spinelli F, Sara R, Milella M, et al. Technetium-99m hexamethylpropylene amine oxime leukocyte scintigrapy in the differential diagnosis of cerebral abscesses. Eur J Nucl Med. 2000;27:46–49
  111. Bar-Shalom R, Yefremov N, Guralnik L, et al. SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. J Nucl Med. 2006;47:587–594

PII: S0001-2998(06)00058-4

doi: 10.1053/j.semnuclmed.2006.08.003

Seminars in Nuclear Medicine
Volume 37, Issue 1 , Pages 34-47 , January 2007

Article Tools

* Image Usage & Resolution